Cancer & Disease Research
ISCT22 co-chair recounts how far CGT industry has come
Advancements in the field of cell and gene therapies (CGTs) have made them a therapeutic reality, according to Bambi Grilley, director of clinical research and early product development at Baylor College of Medicine, and co-chair of the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting. Grilley spoke with ScienceBoard.net at the meeting about the evolution of the CGT industry which is driving clinical translation of CGTs that are benefitting patients. Read More
ISCT22: Scale up of cell therapy manufacturing is a significant, but addressable challenge
The cell therapy industry is facing a significant but addressable challenge when it comes to scaling up manufacturing, according to Bob Newman, PhD, chief scientific officer at FujiFilm Irvine Scientific. ScienceBoard.net spoke with Neman during the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting. Read More
ISCT22: RoosterBio, ShiftBio partner to harness the power of MSCs, exosomes
RoosterBio, a supplier of human mesenchymal stem/stromal cells (MSCs), recently announced a strategic partnership with ShiftBio, a South Korean company that specializes in exosome technology. Tim Kelly, PhD, CEO of RoosterBio, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. Read More
ISCT22: Antion Biosciences CEO highlights new way of approaching allogeneic cell creation
Dr. Sven Kili, CEO of Antion Biosciences, contends the Swiss company’s microRNA (miRNA) technology (miCAR platform) is a new way of approaching allogeneic cell creation by enabling simultaneous silencing of multiple gene targets while overcoming the challenges faced by existing gene editing approaches. Kili spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. Read More
ISCT22: Children's National sees improved cell therapy potency, quicker patient delivery
Children's National Hospital in Washington, DC, is seeing improvements in the potency of existing cell therapies and a reduction in the time it takes to get them to patients, according to Patrick Hanley, PhD, chief and director of the pediatric medical center’s Cellular Therapy Program. Hanley spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. Read More
ISCT22: Orgenesis looks to simplify, lower costs of providing CGT therapies
Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis, told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. However, several factors make CGTs complex, expensive, and difficult to bring to market, including small/personalized batch production and the fact that everything must be conducted in a very sterile environment. Read More
ISCT22: BroadOak’s Poltilove remains bullish on CGT market despite downturn
Bryan Poltilove, partner at BroadOak Capital Partners, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco about how BroadOak’s medium- to long-term investment strategy sees “great science” happening in the sector that’s improving productivity and advancing cell and gene therapies (CGTs), biologics, and other modalities. Read More
ISCT22: Cell therapy has potential to address unmet medical needs in orthopedics
Miguel Forte, CEO of Bone Therapeutics, and president-elect of the International Society for Cell & Gene Therapy (ISCT), spoke with ScienceBoard.net at the ISCT 2022 annual meeting in San Francisco about regenerative medicine and orthopedics. Read More
ISCT working group weighs in on expanded access to CGT
Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded Access Working Group, spoke with ScienceBoard.net at the ISCT 2022 annual meeting in San Francisco about the regulatory and ethical issues around cell and gene therapy (CGT) expanded access. Read More
ISCT president calls for cell and gene therapy education, training amid ‘talent shortage’
This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT) annual meeting. ISCT President Bruce Levine, PhD, professor of cancer gene therapy at the University of Pennsylvania, spoke with ScienceBoard.net at ISCT 2022 about the status and future of the field of cell and gene therapy. Read More
Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter